Please check the resources listed below for more information:

Research and Resources Regarding the Use of Sublingual Immunotherapy (SLIT)

The following is a compilation of scientific research, studies, and other related publications regarding the use of sublingual immunotherapy.

Both international and U.S. allergy leaders and organizations support the safety and effectiveness of SLIT. The American Academy of Otolaryngic Allergy (AAOA) published a dosing schedule protocol for sublingual immunotherapy. In 1998, the World Health Organization endorsed the use of sublingual immunotherapy to treat allergies. In 2007, an international group, which includes U.S. allergists, published the ARIA (Allergy Rhinitis and its Impact on Asthma) guidelines indicating SLIT as a viable treatment to injection therapy.

The Cochrane Collaboration, a non-profit organization that conducts systematic reviews of healthcare options, stated in a Review that sublingual immunotherapy significantly reduces allergy symptoms and the need for allergy medications. Research has also shown that the allergy drops method is safer than allergy shots, based on studies as well as feedback from actual patients.

1. Wahn U, Tabar A, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160-166 e3.

2. Passalacqua G, Pawankar R, Baena-Cagnani C, Canonica G. Sublingual immunotherapy: where do we stand? Present and future. Curr Opin Allergy Clin Immunol. 2009;9:1-3.

3. Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol. 2009; 102:69-75.

4. Jones, SM, editor. Oral immunotherapy promising for children with peanut allergy. Proceedings of the American Academy of Allergy, Asthma & Immunology Annual Meeting; 2009 March 13-17; Washington.

5. Rueff F, Bilo MB, et al. Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy. J Allergy Clin Immunol. 2009;123(1):272-3; author reply 273.

6. van Wijk RG. Sublingual immunotherapy in children. Expert Opin Biol Ther. 2008;8(3):291-8.

7. Van Overtvelt, Lombardi LV, et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol. 2008;145(2):152-62.

8. Tucker MH, and Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol. 2008;101(4):419-25.

9. Tseng SH, Fu LS, et al. Changes in serum specific IgG4 and IgG4/ IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial. Asian Pac J Allergy Immunol. 2008;26(2-3):105-12.

10. Townley RG. Is sublingual immunotherapy ready for prime time? Chest. 2008;133(3):589-90.

11. Tahamiler RG, Saritzali, et al. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec. 2008;70(3):144-50.

12. Svendsen UG. Grazax--treatment for grass pollen hay fever. Ugeskr Laeger. 2008;170(3):135-7.

13. Stiefelhagen P. Specific immunotherapy. Subcutaneous or sublingual? MMW Fortschr Med. 2008;150(24):14, 16.

14. Song JH, Nguyen HH, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proceedings of the National Academy of Science; USA. 2008;105(5):1644-9.

15. Severino MG, Cortellini G, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2008;122(1) 44-8.

16. Saporta D. Sublingual immunotherapy: a novel, albeit not so new, immunotherapy treatment modality. Am J Rhinol. 2008;22(3):253-7.

17. Saltoun C, Avila PC. Advances in upper airway diseases and allergen immunotherapy in 2007. J Allergy Clin Immunol. 2008;122(3):481-7.

18. Rodriguez-Perez N, Ambriz-Moreno Mde MJ, et al. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol. 2008;101(3):304-10.

19. Rodriguez- Santos O. Sublingual immunotherapy in allergic rhinitis and asthma in 2-5 year-old children sensitized to mites. Rev Alerg Mex. 2008;55(2):71-5.

20. Roder E, Berger MY, et al. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol. 2008;19(3):197-207.

21. Roder E, Berger MY, et al. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy. 2008;38(10):1659-67.

22. Rak S. The mechanisms of allergen-specific immunotherapy more clear. Lakartidningen. 2008;105(26-27):1935-7.

23. Railey MD, Adair MA, et al. Allergen immunotherapy for allergic rhinitis. Curr Allergy Asthma Rep. 2008;8(1):1-3.

24. Radtke M, Grammer LC. Subcutaneous administration of allergen vaccines. Clin Allergy Immunol. 2008;21:321-32.

25. Poulsen PB, Pedersen KM, et al. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. Ugeskr Laeger. 2008;170(3):138-42.

26. Pokladnikova J, Krcmova I, et al. Economic evaluation of sublingual vs. subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2008;100(5):482-9.

27. Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2008;100(3):256-63.

28. Penagos M, Passalacqua G, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599-609.

29. Patriarca G, Nucera E, et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol. 2008;21(3):669-77.

30. Passalacqua G, Valovirta E. Adverse effects associated with sublingual immunotherapy. Clin Allergy Immunol. 2008;21:469-75.

31. Passalacqua G, Canonica GW. Administration of sublingual vaccines. Clin Allergy Immunol. 2008;21:333-41.

32. Okubo K, Gotoh M, et al. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol Int. 2008;57(3):265-75.

33. Okamoto Y. Sublingual immunotherapy and Th1 adjuvant immunotherapy. Arerugi. 2008;57(6):685-91.

34. Nucera E, Schiavino D, et al. Sublingual immunotherapy for latex allergy: tolerability and safety profile of rush build-up phase. Curr Med Res Opin. 2008;24(4):1147-54.

35. Nucera E, Schiavino D, et al. Sublingual-oral rush desensitization to mixed cow and sheep milk: a case report. J Investig Allergol Clin Immunol. 2008;18(3):219-22.

36. Nowak-Wegrzyn A, Sicherer SH. Immunotherapy for food and latex allergy. Clin Allergy Immunol. 2008;21:429-46.

37. Mosges R, Koberlein J, et al. Sublingual immunotherapy (SLIT) in the allergologist's practice. MMW Fortschr Med. 2008;150(suppl 2):79-84.

38. Morfin Maciel BM, Castillo Morfin BM. Failure of sublingual immunotherapy to treat latex allergy. A report of a case. Rev Alerg Mex. 2008;55(2):76-81.

39. Marogna M, Tomassetti D, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206-11.

40. Marogna M, Bruno ME, et al. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Allergy Clin Immunol. 2008;40(1):22-9.

41. Marcucci F, Incorvaia C, et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol. 2008;21(3):609-13.

42. Lombardi C, Gargioni S, et al. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy. 2008;63(3):375-6.

43. Lee, CH, Mo JH. Recent advances in immunotherapy of allergic rhinitis. Curr Allergy Asthma Rep. 2008;8(4):269-71.

44. Leatherman, B. Injection and sublingual immunotherapy in the management of allergies affecting the unified airway. Otolaryngol Clin North Am. 2008;41(2):359-74, vii.

45. Larenas-Linnemann DE. Sublingual immunotherapy: dosing in relation to clinical and immunological efficacy. Allergy Asthma Proc. 2008;29(2):130-9.

46. Larenas-Linnemann D, Cox LS. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008;100(2):137-45.

47. Larenas-Linnemann D. Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy. Curr Allergy Asthma Rep. 2008;8(6):465-74.

48. Larenas-Linnemann D, Rodriguez Perez N, et al. Adverse reactions to skin tests and immunotherapy in the practice of Mexican allergologists. Rev Alerg Mex. 2008;55(2):62-70.

49. Larenas-Linnemann D, Guidos Fogelbach GA, et al. Practice patterns in Mexican allergologists about specific immunotherapy with allergens. Rev Alerg Mex. 2008;55(2):53-61.

50. La Shell MS, Calabria CW. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008;101(4):445; author reply 445-6.

51. Kreutzkamp B. Specific immunotherapy in allergy treatment. Evidence for subcutaneous and sublingual administration. Med Monatsschr Pharm. 2008;31(12):473-7.

52. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy. 2008;38(7): 1074-88.

53. Incorvaia C, Frati F, et al. Effects of sublingual immunotherapy on allergic inflammation. Inflamm Allergy Drug Targets. 2008;7(3):167-72.

54. Horiguchi S, Okamoto Y, et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int Arch Allergy Immunol. 2008;146(1):76-84.

55. Hoeks SB, de Groot H, et al. Sublingual immunotherapy in children with asthma or rhinoconjunctivitis: not enough evidence because of poor quality of the studies; a systematic review of literature. Ned Tijdschr Geneeskd. 2008;152(5):261-8.

56. Hedlin G, Arvidsson M. Vaccination against allergies yields good symptom relief. Lakartidningen. 2008;105(26-27): 1938-41.

57. Halken S, Lau S, et al. New visions in specific immunotherapy in children: an iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19 (suppl. 19):60-70.

58. Goswami T, Jasti B, et al. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst. 2008;25(5):449-84.

59. Esch RE, Bush RK, et al. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008;100(5):475-81.

60. Esch RE. Sublingual immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2008;16(3):260-4.

61. Enrique E, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol. 2008;100(3):283-4.

62. Demoly P, Andre C. Information and consent forms for sublingual immunotherapy. Clin Allergy Immunol. 2008;21: 527-34.

63. de Bot CM, Moed H, et al. Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment. BMC Fam Pract. 2008;9:59.

64. Darwish M, Kirby M, et al. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin Drug Investig. 2008;28(1):1-7.

65. Dahl R, Kapp A, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121(2):512-518 e2.

66. D'Anneo RW, Arena A, et al. Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule. Allergol Immunopathol. (Madr) 2008;36(2):79-84.

67. D'Amato G. World Asthma and COPD Forum. Tackling asthma, COPD and allergic diseases. IDrugs. 2008;11(7):486-8.

68. Cox L. Sublingual immunotherapy and allergic rhinitis. Curr Allergy Asthma. 2008;Rep 8(2):102-10.

69. Ciprandi G, Fenoglio D, et al. Sublingual immunotherapy provides an early increase of interferon-gamma production. J Biol Regul Homeost Agents. 2008;22(3):169-73.

70. Ciprandi G, De Amici M, et al. Serum IL-4 as a marker of immunological response to sublingual immunotherapy. J Biol Regul Homeost Agents. 2008;22(2):117-23.

71. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin complexed with beta-cyclodextrin or titrated with crosspovidone--technological approach. Acta Pol Pharm. 2008;65(5):585-9.

72. Calderon MA, Penagos M, et al. Sublingual immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol. 2008;21:359-75.

73. Cadario G, Ciprandi G, et al. Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patient’s satisfaction, quality of life and safety. Int J Immunopathol Pharmacol. 2008;21(2):471-3.

74. Burks AW, Laubach S, et al. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008;121(6):1344-50.

75. Burastero SE, Mistrello G, et al. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Ann Allergy Asthma Immunol. 2008;100(4):343-50.

76. Brand PL. Drops for allergy in children: often applied, but not effective. Ned Tijdschr Geneeskd. 2008;152(5):241-2.

77. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy. 2008;63(3):374.

78. Bissada E, Chacra ZA, et al. Orbitozygomatic complex fracture reduction under local anesthesia and light oral sedation. J Oral Maxillofac Surg. 2008;66(7):1378-82.

79. Bielory L. American Academy of Allergy, Asthma & Immunology--2008 Annual Meeting. IDrugs. 2008;11(5):309-11.

80. Berto P, Frati F, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin. 2008;24(1) 261-6.

81. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev Vaccines. 2008;7(8):1257-76.

82. Batke-Hastings S, Carman TL. Sublingual administration of warfarin: a novel form of delivery. Vasc Med. 2008;13(2):123-6.

83. Antunez C, Mayorga C, et al. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol. 2008;19(3): 210-8.

84. Allam JP, Stojanovski G, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy. 2008;63(6):720-7.

85. Akdis M. Immunologic responses to sublingual allergen immunotherapy. Clin Allergy Immunol. 2008;21:71-86.

86. Grazax for hay fever? Drug Ther Bull. 2008;46(2):9-10.

87. Wiedermann U, Mercenier A. New allergy intervention strategies: hitting the mucosal road. Clin Exp Allergy. 2007;37(4):473-5.

88. Vervloet D, Birnbaum J, et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol. 2007;142(3):239-46.

89. Tahamiler R, Saritzali G, et al. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope. 2007;117(6):965-9.

90. Sun JB, Czerkinsky C, et al. Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand J Immunol. 2007;66(2-3): 278-86.

91. Sharma D, Singhal SR, et al. Sublingual misoprostol in management of missed abortion in India. Trop Doct. 2007;37(1):39-40.

92. Savolainen J, Nieminen K, et al. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy. 2007;62(8):949-53.

93. Saporta D, McDaniel AB. Efficacy comparison of multiple-antigen subcutaneous injection immunotherapy and multiple-antigen sublingual immunotherapy. Ear Nose Throat J. 2007;86(8):493-7.

94. Rossi RE, Monasterolo G, et al. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine. 2007;25(5): 957-64.

95. Roder E, Berger MY, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol. 2007;119(4):892-8.

96. Razafindratsita A, Saint-Lu N, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol. 2007;120(2):278-85.

97. Rak SW, Yang H, et al. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res. 2007;16(2): 191-201.

98. Pham-Thi N, Scheinmann P, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007;18(1):47-57.

99. Passalacqua G, Musarra A, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol. 2007;18(1):58-62.

100. Passalacqua G, Guerra L, et al. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf. 2007;2(2): 117-23.

101. Pajno GB, Caminiti L, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164-70.

102. Pajno GB. Sublingual immunotherapy: the optimism and the issues. J Allergy Clin Immunol. 2007;119(4):796-801.

103. Ozdemir C, Yazi D, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007;18(6):508-15.

104. O'Hehir RE, Sandrini A, et al. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem. 2007;14(21):2235-44.

105. Nuhoglu Y, Ozumut SS, et al. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period. J Investig Allergol Clin Immunol. 2007;17(6):375-8.

106. Nettis E, Colanardi MC, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol. 2007;156(4):674-81.

107. Mosges R, Bruning H, et al. Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial. Acta Dermatovenerol Alp Panonica Adriat. 2007;16(4):143-8.

108. Mosges R. Response to comparison of solutions for sublingual immunotherapy by Claus Bachert. Int Arch Allergy Immunol. 2007;142(4):345.

109. Moreno-Ancillo A, Moreno C, et al. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. J Investig Allergol Clin Immunol. 2007;17(6):399-405.

110. Mauro M, Russello M, et al. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol. 2007;39(4):119-22.

111. Martinez-Canavate Burgos A, Valenzuela-Soria A, et al. Immunotherapy with Alternaria alternata: present and future. Allergol Immunopathol. (Madr) 2007;35(6):259-63.

112. Marogna M, Spadolini I, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol. 2007;98(3):274-80.

113. Marogna M, Bruno M, et al. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol. 2007;142(1):70-8.

114. Marcucci F, Sensi L, et al. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy. 2007;62(12):1475-7.

115. Marcucci F, Sensi L, et al. Sublingual immunotherapy: from safety to mechanism of action. Eur Ann Allergy Clin Immunol. 2007;39(3):101-3.

116. Leatherman BD, Owen S, et al. Sublingual Immunotherapy: Past, present, paradigm for the future? A review of the literature. Otolaryngol Head Neck Surg. 2007;136(suppl 3):S1-20.

117. Larenas-Linnemann DE, Cox LS. Sublingual immunotherapy for asthma: need for high quality meta-analyses to prove the concept. Allergy. 62(6): 2007;704-5;author reply 706-7.

118. La Grutta S, Arena A, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial. Eur Ann Allergy Clin Immunol. 2007;39(2):40-4.

119. Klein F. Instead of hyposensitization by injection. Dissolving immunotherapy under the tongue? MMW Fortschr Med. 2007;149(3):16.

120. Kinaciyan T, Jahn-Schmid B, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol. 2007;119(4):937-43.

121. Kildsgaard J, Brimnes J, et al. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol. 2007;98(4):366-72.

122. Kerzl R, Simonowa A, et al. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J Allergy Clin Immunol. 2007;119(2):507-8.

123. Kay AB. An extract of Timothy-grass pollen used as sublingual immunotherapy for summer hay fever. Drugs Today. (Barc) 2007;43(12):841-8.

124. Ibanez MD, Kaiser F, et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol. 2007;18(6):516-22.

125. Huang CF, Wang CC, et al. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice. Ann Allergy Asthma Immunol. 2007;99(5):443-52.

126. Greenberger PA, Ballow M, et al. Sublingual immunotherapy and subcutaneous immunotherapy: issues in the United States. J Allergy Clin Immunol. 2007;120(6):1466-8.

127. Garcia-Marcos L, Lucas Moreno JM, et al. Sublingual specific immunotherapy: state of the art. Inflamm Allergy Drug Targets. 2007;6(2):117-26.

128. Frew AJ. How does sublingual immunotherapy work? J Allergy Clin Immunol. 2007;120(3):533-6.

129. Frati F, Moingeon P, et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc. v28(1):35-9.

130. Finegold I. Allergen immunotherapy: present and future. Allergy Asthma Proc. 2007;28(1):44-9.

131. Eifan AO, Keles S, et al. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy. 2007;62(5): 567-8.

132. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy. 2007;62(8):954-7.

133. Durham SR. Tradition and innovation: finding the right balance. J Allergy Clin Immunol. 2007;119(4):792-5.

134. Didier A, Malling HJ, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-45.

135. Didier A, De Blay F, et al. Are there specific treatments for allergic asthma?. Rev Mal Respir. 2007;24(8 Pt 3):7S41-51.

136. de Bot CM, Moed H. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children. Pediatr Allergy Immunol. 2007;18(7):627;author reply 628.

137. de Blay F, Barnig C, et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2007;99(5):453-61.

138. Cuburu N, Kweon MN, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine. 2007;25(51):8598-610.

139. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep. 2007;7(6):410-20.

140. Corrigan C. Sublingual immunotherapy. J Allergy Clin Immunol. 2007;119(2):515;author reply 515-7.

141. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy. 2007;62(9):1023-8.

142. Ciprandi G, Fenoglio D, et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc. 2007;28(1) 40-3.

143. Ciprandi G, Agostinis F, et al. Economic evaluation of sublingual immunotherapy: an analysis of literature. Eur Ann Allergy Clin Immunol. 2007;39 Spec. No:21-6.

144. Chitaishvili D, Asatiani T. Sublingual misoprostol prior to manual vacuum aspiration for reducing blood loss at 8-12 weeks of gestation: a randomized double-blind placebo-controlled study. Georgian Med News. 2007; (152):26-30.

145. Calderon MA, Birk AO, et al. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy. 2007;62(8):958-61.

146. Cadario G, Galluccio AG, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007;23(10):2503-6.

147. Brimnes J, Kildsgaard J, et al. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy. 2007;37(4):488-97.

148. Bonini S, Gramiccioni C, et al. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol. 2007;7(5):446-9.

149. Bellanti JA, Settipane AR. Sublingual immunotherapy: a procedure whose time has come? Allergy Asthma Proc. 2007;28(1):1-2.

150. Bahceciler NN, Ozdemir C, et al. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Curr Med Chem. 2007;14(3):265-9.

151. Bachert C, Vestenbaek U, et al. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy. 2007;37(5):772-9.

152. Bachert C. Comparison of solutions for sublingual immunotherapy. Int Arch Allergy Immunol. 2007;142(1):89-90.

153. Arranz B, San L, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol. 2007;22(1):11-5.

154. Andre C, Fadel R. Anaphylaxis caused by allergen sublingual immunotherapy? Allergy. 2007;62(10):1220-1.

155. Alvarez-Cuesta E, Berges-Gimeno P, et al. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy. 2007;62(7):810-7.

156. Altay B, Horasanli K, et al. Double-blind, placebo-controlled, randomized clinical trial of sublingual or intramuscular piroxicam in the treatment of renal colic. A comparative study. Urol Int. 2007;79(1):73-5.

157. Aberer W, Hawranek T, et al. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol. 2007;17(3):131-6.

158. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Eur Ann Allergy Clin Immunol. 2007;38(10):355-60.

159. Werner-Klein M, Kalkbrenner F, et al. Sublingual immunotherapy of allergic diseases. Expert Opin Drug Deliv. 2006;3(5):599-612.

160. Weda M, van Riet-Nales DA, et al. Disintegration of sublingual tablets: proposal for a validated test method and acceptance criterion. Pharmeur Sci Notes. 2006;(2) 41-4.

161. Van Overtvelt L, Razafindratsita A, et al. Sublingual vaccines based on wild-type recombinant allergens. Eur Ann Allergy Clin Immunol. 2006;38(7):247-9.

162. Valovirta E, Jacobsen L, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61(10):1177-83.

163. Tripodi S, Di Rienzo Businco A, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol. 2006;139(2):149-52.

164. Spangfort MD. Update on sublingual immunotherapy treatment regimes. Eur Ann Allergy Clin Immunol. 2006;38(7):244.

165. Skovenborg E. Is Antabus therapy connected with reduced efficacy of nitroglycerin? Ugeskr Laeger. 2006;168(17): 1670;author reply 1670-1.

166. Serra HM, Alignani DO, et al. What do we need to learn to optimize the SLIT alternative? Eur Ann Allergy Clin Immunol. 2006;38(5):158-65.

167. Senti G, Martinez Gomez JM, et al. Immunotherapeutic targeting of allergic disease. Inflamm Allergy Drug Targets. 2006;5(4):243-52.

168. Savolainen J, Jacobsen L, et al. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy. 2006;61(10):1184-90.

169. Rueff F. Special aspects of immunotherapy in children. J Dtsch Dermatol Ges. 2006;4(2):143-52; quiz 153-4.

170. Rodriguez F, Boquete M, et al. Once daily sublingual immunotherapy without updosing--A new treatment schedule. Int Arch Allergy Immunol. 2006;140(4):321-6.

171. Reider N. High-dose sublingual immunotherapy: too much of the good? Ann Allergy Asthma Immunol. 2006;97(2): 125.

172. Potter PC. Update on sublingual immunotherapy. Ann Allergy Asthma Immunol. 2006;96(2)(suppl 1):S22-5.

173. Pham-Thi N, de Blic J, et al. Sublingual immunotherapy in the treatment of children. Allergy. 2006;61 Suppl 81:7-10.

174. Pfaar O, Hormann K, et al. The value and possibilities of immunotherapy in the treatment of allergic rhinitis. MMW Fortschr Med. 2006;148(5):28-32.

175. Penagos M, Compalati E, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol. 2006;97(2):141-8.

176. Passalacqua G, Pasquali M, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61(7):849-54.

177. Passalacqua G, Musarra A, et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol. 2006;117(4):946-8.

178. Passalacqua G, Guerra L, et al. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets. 2006;5(1):43-51.

179. Passalacqua G, Guerra L, et al. New insights in sublingual immunotherapy. Curr Allergy Asthma Rep. 2006;6(5): 407-12.

180. Passalacqua G, Canonica GW. Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol. 2006; 6(6): 449-54.

181. Pancholy SB, Coppola J, et al. Subcutaneous administration of nitroglycerin to facilitate radial artery cannulation. Catheter Cardiovasc Interv. 2006;68(3):389-91.

182. Palma-Carlos AG, Santos AS, et al. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madr). 2006;34(5):194-8.

183. Palma-Carlos AG, Santos AS, et al. Monoid sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2006;38(3): 87-9.

184. Ortolani C, Agostinis F, et al. Practice parameters for sublingual immunotherapy. Monaldi Arch Chest Dis. 2006;65(1):44-6.

185. Nucera E, Schiavino D, et al. Sublingual desensitization in children with congenital malformations and latex allergy. Pediatr Allergy Immunol. 2006;17(8):606-12.

186. Niu, CK, Chen WY, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med. 2006;100(8):1374-83.

187. Musarra A, Cilia M, et al. Survey on the safety of a no-updosing regimen of sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2006;38(9):313-4.

188. Mosges R, Pasch N, et al. Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers. Int Arch Allergy Immunol. 2006;139(4):325-9.

189. Moingeon P, Batard T, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61(2):151-65.

190. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy. 2006;61 (suppl 81):15-9.

191. Mascarell L, Van Overtvelt L, et al. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol Allergy Clin North Am. 2006;26(2):283-306,vii-viii.

192. Marcucci F, Sensi L, et al. Sublingual reactivity to rBET V1 and rPHL P1 in patients with oral allergy syndrome. Int J Immunopathol Pharmacol. 2006;19(1):141-8.

193. Malling HJ, Lund L, et al. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol. 2006;16(3):162-8.

194. Malling HJ. Sublingual immunotherapy: efficacy--methodology and outcome of clinical trials. Allergy. 2006;61 (suppl 81):24-8.

195. Li Y, Xie QM, et al. Desensitization of dust mite drops on antigen-specific asthmatic reaction in guinea pigs. Yao Xue Xue Bao. 2006;41(7):641-6.

196. Larsen TH, Poulsen LK, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study. Allergy. 2006;61(10):1173-6.

197. Kowalski ML. Systemic and specific treatment for a global disease: allergen immunotherapy revisited. Allergy. 2006;61(7):791-5.

198. Kleine-Tebbe J, Ribel M, et al. Safety of a SQ-standardized grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006;61(2):181-4.

199. Kleine-Tebbe J. A bright future for sublingual immunotherapy--contra. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006;(95):242-50;discussion 250-2.

200. Kidon MI, Nelken D. Sublingual immunotherapy--coming of age? Harefuah. 2006;145(2):123-6,165. 201. Khamales S, Bethune-Volters A, et al. A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. Anticancer Drugs. 2006;17(2):217-24.

202. Jutel M, Akdis M, et al. Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy. 2006;61(7):796-807.

203. Ippoliti F, De Santis W, et al. Psychological stress affects response to sublingual immunotherapy in asthmatic children allergic to house dust mite. Pediatr Allergy Immunol. 2006;17(5):337-45.

204. Hellmann A. Allergic rhinitis.This year the pollen count is expected to be high. MMW Fortschr Med. 2006;148(21): 51-2.

205. Heinzerling L, Worm M, et al. Sublingual immunotherapy. J Dtsch Dermatol Ges. 2006;4(5):428-33;quiz 434-5.

206. Guerra L, Compalati E, et al. Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergol Immunopathol (Madr). 2006;34(2):82-3.

207. Giordano T, Quarta C, et al. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Eur Ann Allergy Clin Immunol. 2006;38(9):310-2.

208. Frati F, Incorvaia C, et al. Dose dependence of efficacy but not of safety in sublingual immunotherapy. Monaldi Arch Chest Dis. 2006;65(1):38-40.

209. Enrique E, Cistero-Bahima A. Specific immunotherapy for food allergy: basic principles and clinical aspects. Curr Opin Allergy Clin Immunol. 2006;6(6):466-9.

210. Durham SR, Yang WH, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802-9.

211. Dunsky EH, Goldstein MF, et al. Anaphylaxis to sublingual immunotherapy. Allergy. 2006;61(10):1235.

212. Didier A. Future developments in sublingual immunotherapy. Allergy. 2006;61(suppl 81):29-31.

213. Dehlink E, Eiwegger T, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy. 2006;36(1):32-9.

214. de Bot C, Moed H, et al. Sublingual immunotherapy in children. Re: Marcucci et al. Pediatr Allergy Immunol. 2006;17(4):315;author reply 316-7.

215. de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238-9.

216. Dahl R, Stender A, et al. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61(2):185-90.

217. Dahl R, Kapp A, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118(2):434-40.

218. Cox LS, Larenas Linnemann D, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117(5):1021-35.

219. Cosmi L, Santarlasci V, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy. 2006;36(3):261-72.

220. Ciprandi G, Fenoglio D, et al. Sublingual immunotherapy and regulatory T cells. Allergy. 2006;61(4):511-3.

221. Ciprandi G, Cirillo I, et al. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol. 2006;6(8):1370-3.

222. Canonica GW, Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy. 2006;61 (suppl 81):20-3.

223. Calderon M, Essendrop M. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol. 2006;16(6):338-44.

224. Calamita Z, Saconato H, et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006;61(10):1162-72.

225. Burastero SE. Sublingual immunotherapy for allergic rhinitis: an update. Curr Opin Otolaryngol Head Neck Surg. 2006;14(3):197-201.

226. Bousquet J. A bright future for sublingual immunotherapy?--pro. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006; (95):237-41.

227. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2006;97(2):158-63.

228. Bieber T. Allergen-specific sublingual immunotherapy: less mystic, more scientific. Allergy. 2006;61(2):149-50.

229. Berto P, Passalacqua G, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the sublingual immunotherapy pollen allergy. Italy (SPAI) study. Ann Allergy Asthma Immunol. 2006;97(5):615-21.

230. Bernardini R, Campodonico P, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin. 2006;22(8):1515-22.

231. Bergmann KC. Efficacy and safety of sublingual immunotherapy--a detailed analysis. Pneumologie. 2006;60(4):241-7.

232. Antico A, Pagani M, et al. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006;61(10):1236-7.

233. Akdis CA, Barlan IB, et al. Immunological mechanisms of sublingual immunotherapy. Allergy. 2006;61 (suppl 81): 11-4.

234. Aarnoudse AL, van den Berge H, et al. A localized reaction to sublingual immunotherapy. Ned Tijdschr Geneeskd. 2006;150(29):1632-4.

235. Voltolini S. CATS: avoiding or tolerating? Int J Immunopathol Pharmacol. 2005;18(suppl 4):29-31.

236. Tonnel AB. Specific immunotherapy and therapeutic strategies in allergic diseases. What's new? Bull Acad Natl Med. 2005;189(7):1475-87;discussion 1488-9.

237. Rossi RE, Monasterolo G, et al. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol. 2005;v138(2):105-10.

238. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol. 2005;18(2):277-85.

239. Rolinck-Werninghaus C, Kopp M, et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol. 2005;136(2):134-41.

240. Rienzo VD, Minelli M, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005;35(5):560-4.

241. Reider N. Sublingual immunotherapy for allergic rhinoconjunctivitis--the seeming and the real. Int Arch Allergy Immunol. 2005;137(3):181-6.

242. Passalacqua G, Lombardi C, et al. Sublingual immunotherapy: no more doubts. Eur Ann Allergy Clin Immunol. 2005;37(8):314-20.

243. Olaguibel JM, and Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one metaanalysis. J Investig Allergol Clin Immunol. 2005;15(1):9-16.

244. Mistrello G. LAIS Allergoid. Int J Immunopathol Pharmacol. 2005;18(suppl 4):21-4.

245. Marogna M, Spadolini I, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol. 2005;115(6):1184-8.

246. Marcucci F, Sensi L, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol. 2005;16(6):519-26.

247. Marcucci F, Sensi L, et al. Dose dependence of immunological response to sublingual immunotherapy. Allergy. 2005;60(7):952-6.

248. Lennernas B, Hedner T, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005; 59(2):249-53.

249. Gomez Vera J, Flores Sandoval G, et al. Safety and efficacy of specific sublingual immunotherapy in patients with asthma and allergy to Dermatophagoides pteronyssinus. Rev Alerg Mex. 2005;52(6):231-6.

250. Gidaro GB, Marcucci F, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35(5):565-71.

251. Gammeri E, Arena A, et al. Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol Immunopathol. (Madr). 2005;33(3):142-4.

252. Fiocchi A, Pajno G, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95(3):254-8.

253. Fenoglio D, Puppo F, et al. Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol. 2005;37(4):147-51.

254. Enrique E, Pineda F, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073-9.

255. Didier A. The development of sublingual desensitization. Rev Prat. 2005;55(12):1334.

256. Di Rienzo V. Efficacy and its persistence, in children and adults. Int J Immunopathol Pharmacol. 2005;18(suppl 4): 35-7.

257. Darsow U. Desensitization -- at home and without pricks. How effective is sublingual immunotherapy? Interview by Erik Heintz. MMW Fortschr Med. 2005;147(33-34):15.

258. Ciprandi G, Fenoglio D, et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol. 2005;95(1):38-44.

259. Burastero S. Regarding Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005; 35:565-71. Clin Exp Allergy. 35(10):1407-8;author reply 1409.

260. Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy. 2005;60(1):1-3.

261. Berto P, Bassi M, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol. 2005;37(8):303-8.

262. Bergmann KC. Efficacy and safety of sublingual immunotherapy. Pneumologie. 2005;59(2):136-8.

263. Beato Martinez A, Ayala Mejias S, et al. Sublingual immunotherapy in seasonal allergic rhinitis. Review of 30 cases. Acta Otorrinolaringol Esp. 2005;56(3):112-5.

264. Bahceciler NN, Arikan C, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol. 2005;136(3):287-94.

265. Bagnasco M, Altrinetti V, et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005;138(3):197-202.

266. Baena-Cagnani CE, Passalacqua G, et al. Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Curr Opin Allergy Clin Immunol. 2005;5(2):173-7.

267. Ariano R, Panzani RC, et al. Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data. Eur Ann Allergy Clin Immunol. 2005;37(3):103-8.

268. Agostinis F, Tellarini L, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005; 60(1):133.

269. Valovirta E, Passalacqua G, et al. Non-injection routes for immunotherapy of allergic diseases. Clin Allergy Immunol. 2004;18:607-23.

270. Tonnel AB, Scherpereel A, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy. 2004;59(5):491-7.

271. Tang OS, Mok KH, et al. A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester. Hum Reprod. 2004;19(5):1101-4.

272. Sopo SM, Macchiaiolo M, et al. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child. 2004;89(7):620-4.

273. Smith H, White P, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):831-7.

274. Senna G, Passalacqua G, et al. Position paper: controversial and unproven diagnostic procedures for food allergy. Eur Ann Allergy Clin Immunol. 2004;36(4):139-45.

275. Rolinck-Werninghaus C, Wolf H, et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy. 2004;59(12):1285-93.

276. Rodriguez Santos O. Sublingual immunotherapy with allergenic extract of Dermatophagoides pteronyssinus in asthmatic children. Rev Alerg Mex. 2004;51(5):177-80.

277. Pereira C, Botelho F, et al. Kinetics and dynamic evaluation of specific immunotherapy. Eur Ann Allergy Clin Immunol. 2004;36(10):375-86.

278. Passalacqua G, Lombardi C, et al. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol. 2004;4(1): 31-6.

279. Passalacqua G, Guerra L, et al. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol. 2004;93(1):3-12;quiz 12-3, 103.

280. Passalacqua G, Canonica GW. Sublingual or injection immunotherapy: the final answer? Allergy. 2004;59(1):37-8.

281. Olive Perez A. Sublingual vs subcutaneous immunotherapy. Rev Alerg Mex. 2004;51(1):29-35.

282. Novembre E, Galli E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851-7.

283. Norman PS. Sublingual swallow immunotherapy in the new world. Ann Allergy Asthma Immunol. 2004;93(5):405-6.

284. Mosges R. The role of hyposensitization: do we need to start rethinking? Curr Opin Allergy Clin Immunol. 2004;4(3):155-7.

285. Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol. 2004;5(5):281-94.

286. Marogna M, Spadolini I, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy. 2004;59(11):1205-10.

287. Malling HJ. Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. Curr Opin Allergy Clin Immunol. 2004;4(6):539-42.

288. Lombardi C, Gani F, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol. 2004;113(6):1219-20.

289. Ledford DK. Is oral immunotherapy too good to be true? Ann Allergy Asthma Immunol. 2004;92(1):1-2.

290. Khinchi MS, Poulsen LK, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59(1):45-53.

291. Just J, Goudard E, et al. Past and future of allergen immunotherapy. Arch Pediatr. 2004;(11) (suppl 2):74s-79s.

292. Halloy JL. Sublingual hyposensitization. Rev Med Brux. 2004;25(4):A256-8.

293. Cistero Bahima A, Sastre J, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol. 2004;14(1):17-25.

294. Canonica GW, Compalati E, et al. Sublingual and oral immunotherapy. Immunol Allergy Clin North Am. 2004;24(4): 685-704,vii.

295. Bufe A, Ziegler-Kirbach E, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy. 2004;59(5):498-504.

296. Bowen T, Greenbaum J, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2004;93(5):425-30.

297. Zwacka G, Markert UR. Therapeutic procedures of sublingual immunotherapy in clinical practice. Chem Immunol Allergy. 2004;82: 44-52.

298. Zou J, Lu H, et al. Clinical study of watermelon frost runhou tablet treatment for pharynx and larynx oral cavity. Lin Chuang Er Bi Yan Hou Ke ZaZhi. 2003;17(4):253-5.

299. Wuthrich B, Bucher C, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol. 2003;13(3):145-8.

300. Wilson DR, Torres LI, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003;(2): CD002893.

301. Wild DC, Spraggs PD. Sublingual packing as an useful adjunct to submandibular gland excision. Clin Otolaryngol Allied Sci. 2003;28(1):22-3.

302. Wessner D, Rakoski J, et al. Efficacy of sublingual immunotherapy in grass pollen allergy. Chem Immunol Allergy. 2003;82:53-61.

303. Sambugaro R, Puccinelli P, et al. The efficacy of sublingual immunotherapy for respiratory allergy is not affected by different dosage regimens in the induction phase. Allergol Immunopathol (Madr). 2003;31(6):329-37.

304. Reich M, Zwacka G, et al. Nonspecific plasma proteins during sublingual immunotherapy. Chem Immunol Allergy. 2003;82;99-108.

305. Passalacqua G, Guerra Enrico Compalati L, et al. Sublingual immunotherapy. Rev Alerg Mex. 2003;50(6):220-5.

306. Passalacqua G, Fumagalli F, et al. Safety of allergen-specific sublingual immunotherapy and nasal immunotherapy. Chem Immunol Allergy. 2003;82109-18.

307. Passalacqua G, Canonica GW. Oral, nasal and sublingual immunotherapy: do they work, are they safe? Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003;(94):126-30;discussion 130-2.

308. Passalacqua G, Baena-Cagnani CE, et al. Oral and sublingual immunotherapy in paediatric patients. Curr Opin Allergy Clin Immunol. 2003;3(2):139-45.

309. Pajno GB, Vita D, et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy. 2003;33(12):1641-7.

310. Pajno GB, D. Peroni G, et al. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003;5(11):777-81.

311. Pajno GB, Peroni DG, et al. Efficacy of sublingual immunotherapy in asthma and eczema. Chem Immunol Allergy. 2003;82:77-88.

312. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol. 2003;111(suppl 3): S793-8.

313. Morris DL, Morris MS, et al. Allergen immunotherapy. Ann Allergy Asthma Immunol. 2003;91(1):96;author reply 97-8.

314. Morris DL, Kroker GF, et al. Local immunotherapy in allergy. Chem Immunol Allergy. 2003;82:1-10.

315. Mastrandrea F, Nicotra MR, et al. Mite antigens enhance ICAM-1 and induce VCAM-1 expression on human umbilical vein endothelium. Allergol Immunopathol (Madr). 2003;31(5):259-64.

316. Markert UR. Local immunotherapy in allergy: prospects for the future. Chem Immunol Allergy. 2003;82:127-35.

317. Marcucci F, Sensi L, et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy. 2003;58(7):657-62.

318. Malling HJ. Immunotherapy for rhinitis. Curr Allergy Asthma Rep. 2003; 3(3):204-9.

319. Madonini E, Agostinis F, et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol. 2003;16(1):73-9.

320. Lleonart R, Munoz F, et al. Sublingual immunotherapy in children. Immunotherapy Committee of the Spanish Society for Clinical Immunology and Pediatric Allergology. Allergol Immunopathol (Madr). 2003;31(4):244-9.

321. Jorde W, Jorde UP. Antigen resorption from the gastrointestinal tract. A historical perspective on the pathophysiological foundation of modern sublingual/oral immunotherapy. Chem Immunol Allergy. 2003;82:25-32.

322. Guez S. Efficacy of desensitization via the sublingual route in mite allergy. Chem Immunol Allergy. 2003;82:62-76.

323. Grevers G. Specific immunotherapy in desensitization of allergic patients. Oral administration instead of injections? (interview by Andrea Warpakowski). MMW Fortschr Med. 2003;145(18):18.

324. Frati F, Sensi L, et al. A model for management of sublingual immunotherapy. Eur Ann Allergy Clin Immunol. 2003;35(2):56-60.

325. Di Rienzo V, Marcucci F, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33(2):206-10.

326. Cirla AM, Cirla PM, et al. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two-year controlled study. Allergol Immunopathol (Madr). 2003;31(1):31-43.

327. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol. 2003;111(3):437-48; quiz 449.

328. Bujold E, Marquette GP, et al. Sublingual nitroglycerin versus intravenous ritodrine as tocolytic for external cephalic version: a double-blinded randomized trial. Am J Obstet Gynecol. 2003;188(6):1454-7;discussion 1457-9.

329. Bagnasco M, Morbelli S, et al. Allergen biodistribution in humans. Chem Immunol Allergy. 2003;82:33-43.

330. Andre C, Perrin-Fayolle M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol. 2003;131(2):111-8.

331. Sublingual immunotherapy for allergies. TEC Bull (Online) 2003;20(1):27-31.

332. Wahn U. Immunotherapy in children. Curr Opin Allergy Clin Immunol. 2002;2(6): 557-60.

333. Reiber ME. Sublingual administration of allergen desensitization. Tenn Med. 2002;95(11):465-7.

334. Patriarca G, Nucera E, et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg. 2002;95(4):956-60,table of contents.

335. Malling HJ. Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol. 2002;2(6):523-31.

336. Grosclaude M, Bouillot P, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol. 2002;129(3):248-53.

337. Douglass J, O'Hehir R. Specific allergen immunotherapy: time for alternatives? Clin Exp Allergy. 2002;32(1):1-3.

338. Voltolini S, Modena P, et al. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardized extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr). 2001;29(4):103-10.

339. Sanchez Palacios A, Schamann F, et al. Sublingual immunotherapy with cat epithelial extract. Personal experience. Allergol Immunopathol. (Madr). 2001;29(2):60-5.

340. Rakoski J, Wessner D. A short assessment of sublingual immunotherapy. Int Arch Allergy Immunol. 2001;126(3): 185-7.

341. Passalacqua G, Villa G, et al. Sublingual swallow or spit? Allergy. 2001;56(6):578.

342. Passalacqua G, Canonica GW. Allergen-specific sublingual immunotherapy for respiratory allergy. BioDrugs. 2001;15(8):509-19.

343. Lombardi C, Gargioni S, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy. 2001;56(10):989-92.

344. Frew AJ ,Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol. 2001;107(3):441-4.

345. Brown JL, Frew AJ. The efficacy of oromucosal immunotherapy in respiratory allergy. Clin Exp Allergy. 2001;31(1): 8-10.

346. Bahceciler NN, Isik U, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol. 2001;32(1):49-55.

347. Bagnasco M, Passalacqua G, et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy. v31(1):54-60.

348. Ariano R, Spadolini I, et al. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madr). 2001;29(6):238-44.

349. Valle C, Bazzi S, et al. Effects of sublingual immunotherapy in patients sensitised to Ambrosia. An open controlled study. Allergol Immunopathol(Madr). 2000;28(6):311-7.

350. Pajno GB, Morabito L, et al. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy. 2000;55(9):842-9.

351. Munoz-Lopez F. New administration routes in immunotherapy. Allergol Immunopathol (Madr). 2000;28(6):295-300.

352. Miller BE, De Souza MJ, et al. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density. Menopause. 2000;7(5):318-26.

353. Mastrandrea F, Serio G, et al. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr). 2000;28(2):54-62.

354. Mastrandrea F, Coradduzza G, et al. T-cell receptor Vbeta repertoire in mite-allergic subjects after sublingual immunotherapy. J Investig Allergol Clin Immunol. 2000;10(3):142-8.

355. Martorell Aragones A. New administration routes for immunotherapy. Allergol Immunopathol (Madr). 2000;28(3): 93-102.

356. Lombardi C, Canonica GW, et al. Sublingual IT in OAS. Allergy. 2000;55(7):677-8.

357. Guez S, Vatrinet C, et al. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy. 2000;55(4):369-75.

358. Fuchs,T, Klimek L. Allergen-specific immunotherapy (hyposensitization). Part 2. Oral, sublingual and nasal application. HNO 2000;48(2):158-64.

359. Durham SR, Walker S. Immunotherapy for hayfever. Chem Immunol. 2000;78:199-208.

360. Demoly P, Dhivert-Donnadieu H, et al. Vaccination with allergens in children. Allerg Immunol (Paris). 2000;32(10): 397-401.

361. Andre C, Vatrinet C, et al. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol. 2000;121(3):229-34.

362. Purello-D'Ambrosio F, Gangemi S, et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy. 1999;54(9):968-73.

363. Pradalie, A, Basset D, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy. 1999;54(8): 819-28.

364. Passalacqua G, Venturi S, et al. Oral and sublingual immunotherapy: general aspects and critical considerations. Wien Med Wochenschr. 1999;149(14-15):433-7.

365. Passalacqua G, Albano M, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol. 1999;104(5): 964-8.

366. Mungan D, Misirligil Z, et al. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Ann Allergy Asthma Immunol. 1999;82(5): 485-90.

367. Morris DL. WHO position paper on oral (sublingual) immunotherapy. Ann Allergy Asthma Immunol. 1999;83(5): 423-4.

368. Malling HJ. Allergen-specific immunotherapy. Present state and directions for the future. Allergy. 1999;54 Suppl 50:30-3.

369. La Rosa M, Ranno C, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999;104(2 Pt 1):425-32.

370. Horak F. Oral and sublingual specific immunotherapy (SIT). Allergy. 1999;54(suppl 56): 41-2.

371. Frew AJ, White PJ, et al. Sublingual immunotherapy. J Allergy Clin Immunol. 1999;104(2 Pt 1):267-70.

372. Di Rienzo V, Puccinelli P, et al. Grass pollen specific sublingual/swallow immunotherapy in children: open-controlled comparison among different treatment protocols. Allergol Immunopathol (Madr).1999;27(3): 145-51.

373. Di Rienzo V, Pagani A, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy. 1999;54(10):1110-3.

374. Bousquet J, Scheinmann P, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy. 1999;54(3):249-60.

375. Bousquet J. Local routes of immunotherapy. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1999; (93):121-7;discussion 128-9.

376. Vourdas D, Syrigou E, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998;53(7):662-72.

377. Sabbah A. Apropos of sublingual specific immunotherapy. Allerg Immunol (Paris). 1998;30(4):97-8.

378. Sabbah A. Specific immunotherapy using allergens apropos of specific immunotherapy by the sublingual

379. route. Allerg Immunol (Paris). 1998;30(7):221-8.

380. Horak F, Stubner P, et al. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol. 1998;8(3):165-71.

381. Holt PG, Sly PD, et al. Sublingual immunotherapy for allergic respiratory disease. Lancet. 1998;351(9103):613-4.

382. Clavel R, Bousquet J, et al. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized fivegrass-pollen extract in rhinitis. Allergy. 1998;53(5):493-8.

383. Canonica GW, Passalacqua G, et al. Oral routes for immunotherapy: clinical efficacy and kinetics of the allergen. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1997; (91):56-64;discussion 64-7.

384. Quirino T, Lemoli E, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996;26(11):1253-61.

385. Malling HJ. Sublingual immunotherapy. Clin Exp Allergy. 1996;26(11):1228-31.

386. van Wilsem EJ, Breve J, et al. Oral tolerance is determined at the level of draining lymph nodes. Immunobiology. 1995;194(4-5):403-14.

387. Troise C, Voltolini S, et al. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol. 1995;5(1):25-30.

388. Feliziani V, Lattuada G, et al. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr). 1995;23(5):224-30.

389. Bousquet J, Michel FB, et al. Sublingual immunotherapy for cat allergy. J Allergy Clin Immunol. 1995;95(4):920-1.

390. Sabbah A, Hassoun S, et al. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy. 1994;49(5):309-13.

391. Igea JM, Cuevas M, et al. Susceptibility of a grass-pollen oral immunotherapy extract to the saliva and gastric fluid digestive process. Allergol Immunopathol (Madr). 1994;22(2):55-9.

392. Sabbah A, Lesellin J, et al. Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens. Allerg Immunol (Paris). 1993;25(6):241-7.

393. Nelson HS, Oppenheimer J, et al. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol.1993; 92(2):229-36.

394. Feliziani V, Marfisi RM, et al. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr). 1993;21(5):173-8.

395. Tari MG, Mancino M, et al. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr). 1990;18(5):277-84.

396. King DS. The reliability and validity of provocative food testing: a critical review. Med Hypotheses. 1988;25(1):7-16.

397. Holt PG, Vines J, et al. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin Allergy. 1988;18(3):229-34.

Designed by The Creative Perspective, LLC

© Copyright 2008 All-American Allergy Alternatives, LLC
All rights reserved